The content on this site is intended solely for New Zealand residents. It is intended for informational purposes only and should not be used to replace a discussion with a healthcare professional. All decisions made regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient. The person shown is from stock photography (model) and is not an actual patient. This website has been developed and is funded by AbbVie Limited. Wellington.
MAVIRET is a fully funded medicine with an alternative arrangement on how it is available to you. Your prescriber will explain this to you.
IMPORTANT INFORMATION ABOUT MAVIRET®
MAVIRET® is a prescription medicine containing a combination tablet of 100 mg of glecaprevir and 40 mg of pibrentasvir. It is used to treat adults and adolescents 12 years and older with chronic (long-lasting) hepatitis C virus (HCV). This medicine belongs to a group of medicines called direct-acting antiviral agents. Ask your doctor if you have any questions about why MAVIRET® has been prescribed for you.
MAVIRET has risks and benefits. You must not take MAVIRET® if you are allergic to any of the medicines contained in MAVIRET®, or to any of the inactive ingredients. Do not take it if you have severe liver disease; if you are taking atazanavir or rifampicin containing products. Before you use MAVIRET®, tell your doctor if you have or have had liver problems other than hepatitis C infection, HIV infection, hepatitis B infection, or a liver or kidney transplant. Tell your doctor or pharmacist if you have or have had diabetes. Tell your doctor or pharmacist if you are pregnant, trying to become pregnant or if you are breastfeeding or are planning to breastfeed. Do not give MAVIRET® to a child under the age of 12 years. Some medicines and MAVIRET® may interfere with each other, so tell your doctor if you are taking medicines containing any of the following: atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, carbamazepine, ciclosporin, darunavir, lopinavir, ritonavir, efavirenz, dabigatran, digoxin, ethinyloestradiol, fluindione, warfarin or other vitamin K antagonists, St John's wort. Some of the more common side effects of MAVIRET® include feeling very tired, headache and nausea. Other side effects may occur in some people. Tell your doctor, nurse or pharmacist if you notice anything that is making you feel unwell.
If you have any questions about using MAVIRET, including its risks and benefits, how much to use, how and when to use it, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available from the Medsafe website www.medsafe.govt.nz or free phone 0800 900 030. Ask your doctor if MAVIRET is right for you. Normal doctor's charges apply. Always use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.
©2025 AbbVie. All rights reserved. AbbVie® is a registered trademark of AbbVie Inc. MAVIRET® is a registered trademark of AbbVie Manufacturing Management Unlimited Company.
AbbVie Privacy
Personal data about you collected by AbbVie Pty Ltd and/or AbbVie Limited, both AbbVie companies (“AbbVie”) is subject to our Privacy Notice, https://www.abbvie.co.nz/privacy.html, which describes how AbbVie collects and processes your personal data and your data privacy rights. Providing your personal data to us is voluntary, but if you decide not to provide us with your personal data, AbbVie may not be able to provide you with certain services.
MAVIRET is supplied in New Zealand by AbbVie Limited, L6, 156-158 Victoria Street, Wellington, 6011, New Zealand 0800 900 030.
TAPS BG5650. NZ-MAVI-250024. Date of revision November 2025.
